ACTRN12620000566932终止3 期
BEAT COVID-19: A Bayesian adaptive platform, randomised controlled Trial to evaluate the efficacy and safety of interventions for COVID-19.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 195
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.Adult, aged greater than or equal to 18 years.
- •2.PCR or RAT-confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
- •3.Intention for community-based management.
- •4.Eligibility to at least one recruiting domain.
- •5.Participant & treating clinician are willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments, and.
- •6.Documented informed consent
排除标准
- •1. Currently pregnant or breast-feeding
- •2. Any medical condition which, in the opinion of the Investigator, may affect the participant’s safety or study participation and conduct
研究者
相似试验
尚未招募
不适用
Software for COVID19 Detection from Chest X-Ray, CT or UltrasonographyCTRI/2020/07/026351PurplAS IT Services Pvt Ltd
已完成
不适用
ASTERIX: An observational study to identify sub-groups of COVID-19 patients based on their demographic, clinical and laboratory profile, and to determine if these sub-groups can be used to predict severity of disease and response to therapyCOVID-19 (SARS-CoV-2 infection)Infections and InfestationsISRCTN66141262HS Greater Glasgow and Clyde6,000
进行中（未招募）
1 期
Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.EUCTR2020-001243-15-BEZLeuven200
进行中（未招募）
1 期
Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.COVID-19MedDRA version: 20.0Level: LLTClassification code 10038700Term: Respiratory infectionSystem Organ Class: 100000004862EUCTR2020-001614-38-BEZLeuven282
招募中
不适用
HERALDPER-106-20CureVac AG,7,448